Skip to main content

Articles

Page 9 of 38

  2. The bispecific antibody (bsAbs) research around the world has undergone great changes. We analyzed the global trend of bsAbs research and compared the differences in clinical research of bsAbs between China an...

    Authors: Zhonghan Zhang, Fan Luo, Jiaxin Cao, Feiteng Lu, Yang Zhang, Yuxiang Ma, Kangmei Zeng, Li Zhang and Hongyun Zhao
    Citation: Journal of Hematology & Oncology 2021 14:124
    Content type: Letter to the Editor Published on:

  3. Thromboembolism is a frequent cause of severity and mortality in COVID-19. However, the etiology of this phenomenon is not well understood. A cohort of 1186 subjects, from the GEN-COVID consortium, infected by...

    Authors: Chiara Fallerini, Sergio Daga, Elisa Benetti, Nicola Picchiotti, Kristina Zguro, Francesca Catapano, Virginia Baroni, Simone Lanini, Alessandro Bucalossi, Giuseppe Marotta, Francesca Colombo, Margherita Baldassarri, Francesca Fava, Giada Beligni, Laura Di Sarno, Diana Alaverdian…
    Citation: Journal of Hematology & Oncology 2021 14:123
    Content type: Letter to the Editor Published on:

    The Correction to this article has been published in Journal of Hematology & Oncology 2023 16:11

  4. During acute myeloid leukemia (AML) growth, the bone marrow (BM) niche acquires significant vascular changes that can be offset by therapeutic blast cytoreduction. The molecular mechanisms of this vascular pla...

    Authors: Bin Zhang, Le Xuan Truong Nguyen, Dandan Zhao, David E. Frankhouser, Huafeng Wang, Dinh Hoa Hoang, Junjing Qiao, Christina Abundis, Matthew Brehove, Yu-Lin Su, Yuxin Feng, Anthony Stein, Lucy Ghoda, Adrianne Dorrance, Danilo Perrotti, Zhen Chen…
    Citation: Journal of Hematology & Oncology 2021 14:122
    Content type: Research Published on:

  5. MYC oncogene is a transcription factor with a wide array of functions affecting cellular activities such as cell cycle, apoptosis, DNA damage response, and hematopoiesis. Due to the multi-functionality of MYC,...

    Authors: Seyed Esmaeil Ahmadi, Samira Rahimi, Bahman Zarandi, Rouzbeh Chegeni and Majid Safa
    Citation: Journal of Hematology & Oncology 2021 14:121
    Content type: Review Published on:

    The Correction to this article has been published in Journal of Hematology & Oncology 2021 14:135

  6. Pancreatic cancer’s poor prognosis is caused by distal metastasis, which is associated with epigenetic changes. However, the role of the 3D epigenome in pancreatic cancer biology, especially its metastasis, re...

    Authors: Bo Ren, Jinshou Yang, Chengcheng Wang, Gang Yang, Huanyu Wang, Yuan Chen, Ruiyuan Xu, Xuning Fan, Lei You, Taiping Zhang and Yupei Zhao
    Citation: Journal of Hematology & Oncology 2021 14:120
    Content type: Research Published on:

  7. In a population of 42 Philadelphia negative myeloproliferative neoplasm patients, all on systemic active treatment, the likelihood of responding to anti-SARS-CoV-2 BNT162b2 vaccine at 2 weeks after the second ...

    Authors: Fulvia Pimpinelli, Francesco Marchesi, Giulia Piaggio, Diana Giannarelli, Elena Papa, Paolo Falcucci, Antonio Spadea, Martina Pontone, Simona Di Martino, Valentina Laquintana, Antonia La Malfa, Enea Gino Di Domenico, Ornella Di Bella, Gianluca Falzone, Fabrizio Ensoli, Branka Vujovic…
    Citation: Journal of Hematology & Oncology 2021 14:119
    Content type: Letter to the Editor Published on:

  8. Although chimeric antigen receptor (CAR)-engineered T cells have shown great success in the treatment of B cell malignancies, this strategy has limited efficacy in patients with solid tumors. In mouse CAR-T ce...

    Authors: Nengzhi Pang, Jingxuan Shi, Le Qin, Aiming Chen, Yuou Tang, Hainan Yang, Yufeng Huang, Qingde Wu, Xufeng Li, Bingjia He, Tianheng Li, Baoxia Liang, Jinglin Zhang, Bihui Cao, Manting Liu, Yunfei Feng…
    Citation: Journal of Hematology & Oncology 2021 14:118
    Content type: Letter to the Editor Published on:

  9. N6-methyladenosine (m6A) has emerged as an abundant modification throughout the transcriptome with widespread functions in protein-coding and noncoding RNAs. It affects the fates of modified RNAs, including th...

    Authors: Wei Huang, Tian-Qi Chen, Ke Fang, Zhan-Cheng Zeng, Hua Ye and Yue-Qin Chen
    Citation: Journal of Hematology & Oncology 2021 14:117
    Content type: Review Published on:

  10. RAS mutations (HRAS, NRAS, and KRAS) are among the most common oncogenes, and around 19% of patients with cancer harbor RAS mutations. Cells harboring RAS mutations tend to undergo malignant transformation and ex...

    Authors: Kun Chen, Yalei Zhang, Ling Qian and Peng Wang
    Citation: Journal of Hematology & Oncology 2021 14:116
    Content type: Review Published on:

  12. Metabolic rewiring offers novel therapeutic opportunities in cancer. Until recently, there was scant information regarding soft tissue sarcomas, due to their heterogeneous tissue origin, histological definitio...

    Authors: Richard Miallot, Franck Galland, Virginie Millet, Jean-Yves Blay and Philippe Naquet
    Citation: Journal of Hematology & Oncology 2021 14:114
    Content type: Review Published on:

  13. Relapses of CD19-expressing leukemia in patients who achieved initial remission after CART cell treatment have been reported to correlate with poor CART cells persistence. Sustained tonic signaling or strong a...

    Authors: Hao Zhang, Yongxian Hu, Mi Shao, Xinyi Teng, Penglei Jiang, Xiujian Wang, Hui Wang, Jiazhen Cui, Jian Yu, Zuyu Liang, Lijuan Ding, Yingli Han, Jieping Wei, Yulin Xu, Xiaoqing Li, Wei Shan…
    Citation: Journal of Hematology & Oncology 2021 14:113
    Content type: Letter to the Editor Published on:

  14. Long non-coding RNAs (lncRNAs) are important epigenetic regulators, which play critical roles in diverse physiological and pathological processes. However, the regulatory mechanism of lncRNAs in lung carcinoge...

    Authors: Xinyi Qian, Juze Yang, Qiongzi Qiu, Xufan Li, Chengxi Jiang, Jia Li, Liangliang Dong, Kejing Ying, Bingjian Lu, Enguo Chen, Pengyuan Liu and Yan Lu
    Citation: Journal of Hematology & Oncology 2021 14:112
    Content type: Research Published on:

  15. Patients with RR DLBCL who have received ≥ 2 lines of therapy have limited treatment options and an expected overall survival (OS) of < 6 months. The SADAL study evaluated single-agent oral selinexor in patien...

    Authors: Marie Maerevoet, Josee M. Zijlstra, George Follows, Rene-Olivier Casasnovas, J. S. P. Vermaat, Nagesh Kalakonda, Andre Goy, Sylvain Choquet, Eric Van Den Neste, Brian Hill, Catherine Thieblemont, Federica Cavallo, Fatima De la Cruz, John Kuruvilla, Nada Hamad, Ulrich Jaeger…
    Citation: Journal of Hematology & Oncology 2021 14:111
    Content type: Letter to the Editor Published on:

  16. CPX-351 (United States: Vyxeos®; Europe: Vyxeos® Liposomal), a dual-drug liposomal encapsulation of daunorubicin and cytarabine in a synergistic 1:5 molar ratio, is approved by the US FDA and the EMA for the trea...

    Authors: Jorge E. Cortes, Tara L. Lin, Geoffrey L. Uy, Robert J. Ryan, Stefan Faderl and Jeffrey E. Lancet
    Citation: Journal of Hematology & Oncology 2021 14:110
    Content type: Research Published on:

  17. The prognosis for diffuse gliomas is very poor and the mechanism underlying their malignant progression remains unclear. Here, we aimed to elucidate the role and mechanism of the RNA N6,2′-O-dimethyladenosine (m6

    Authors: Rui-Chao Chai, Yu-Zhou Chang, Xin Chang, Bo Pang, Song Yuan An, Ke-Nan Zhang, Yuan-Hao Chang, Tao Jiang and Yong-Zhi Wang
    Citation: Journal of Hematology & Oncology 2021 14:109
    Content type: Research Published on:

  19. Recently, a novel knowledge bank (KB) approach to predict outcomes of individual patients with acute myeloid leukemia (AML) was developed using unbiased machine learning. To validate its prognostic value, we a...

    Authors: Marius Bill, Krzysztof Mrózek, Brian Giacopelli, Jessica Kohlschmidt, Deedra Nicolet, Dimitrios Papaioannou, Ann-Kathrin Eisfeld, Jonathan E. Kolitz, Bayard L. Powell, Andrew J. Carroll, Richard M. Stone, Ramiro Garzon, John C. Byrd, Clara D. Bloomfield and Christopher C. Oakes
    Citation: Journal of Hematology & Oncology 2021 14:107
    Content type: Letter to the Editor Published on:

  20. CD19-directed chimeric antigen receptor T cell (CART19) therapy is efficient and approved for relapsed/refractory diffuse large B cell lymphoma (DLBCL). To increase durable antitumor response, we previously de...

    Authors: Chunmeng Wang, Fengxia Shi, Yang Liu, Yajing Zhang, Liang Dong, Xiang Li, Chuan Tong, Yao Wang, Liping Su, Jing Nie and Weidong Han
    Citation: Journal of Hematology & Oncology 2021 14:106
    Content type: Letter to the Editor Published on:

    The Correction to this article has been published in Journal of Hematology & Oncology 2021 14:150

  21. FLT3 mutations are the most frequently identified genetic alterations in acute myeloid leukemia (AML) and are associated with poor prognosis. Multiple FLT3 inhibitors are in various stages of clinical evaluati...

    Authors: Peihong Wang, Xinhua Xiao, Yuyin Zhang, Baoyuan Zhang, Donghe Li, Mingzhu Liu, Xi Xie, Chenxuan Liu, Ping Liu and Ruibao Ren
    Citation: Journal of Hematology & Oncology 2021 14:105
    Content type: Letter to the Editor Published on:

  23. The Philadelphia negative myeloproliferative neoplasms (MPN) compromise a heterogeneous group of clonal myeloid stem cell disorders comprising polycythaemia vera, essential thrombocythaemia and primary myelofi...

    Authors: Graeme Greenfield, Mary Frances McMullin and Ken Mills
    Citation: Journal of Hematology & Oncology 2021 14:103
    Content type: Review Published on:

  24. T-cell receptor (TCR)-based adoptive therapy employs genetically modified lymphocytes that are directed against specific tumor markers. This therapeutic modality requires a structured and integrated process th...

    Authors: Apostolia-Maria Tsimberidou, Karlyle Van Morris, Henry Hiep Vo, Stephen Eck, Yu-Feng Lin, Jorge Mauricio Rivas and Borje S. Andersson
    Citation: Journal of Hematology & Oncology 2021 14:102
    Content type: Review Published on:

  25. KPT-9274 is a phase 1 first-in-class dual PAK4/NAMPT inhibitor for solid tumor and non-Hodgkin’s lymphoma. It demonstrates pre-clinical efficacy toward a broad spectrum of acute myeloid leukemia (AML) subtypes...

    Authors: Shaneice Mitchell, Pu Zhang, Matthew Cannon, Larry Beaver, Amy Lehman, Bonnie Harrington, Deepa Sampath, John C. Byrd and Rosa Lapalombella
    Citation: Journal of Hematology & Oncology 2021 14:101
    Content type: Letter to the Editor Published on:

  26. Although checkpoint-based immunotherapy has shown exciting results in the treatment of tumors, around 70% of patients have experienced unresponsiveness. PVRIG is a recently identified immune checkpoint recepto...

    Authors: Yangyang Li, Yu Zhang, Guoshuai Cao, Xiaodong Zheng, Cheng Sun, Haiming Wei, Zhigang Tian, Weihua Xiao, Rui Sun and Haoyu Sun
    Citation: Journal of Hematology & Oncology 2021 14:100
    Content type: Research Published on:

  27. The human ζ-globin gene (HBZ) is transcribed in primitive erythroid cells only during the embryonic stages of development. Reactivation of this embryonic globin synthesis would likely alleviate symptoms both in α...

    Authors: Huiqiao Chen, Zixuan Wang, Shanhe Yu, Xiao Han, Yun Deng, Fuhui Wang, Yi Chen, Xiaohui Liu, Jun Zhou, Jun Zhu and Hao Yuan
    Citation: Journal of Hematology & Oncology 2021 14:99
    Content type: Letter to the Editor Published on:

  28. Tumors are not only aggregates of malignant cells but also well-organized complex ecosystems. The immunological components within tumors, termed the tumor immune microenvironment (TIME), have long been shown t...

    Authors: Tong Fu, Lei-Jie Dai, Song-Yang Wu, Yi Xiao, Ding Ma, Yi-Zhou Jiang and Zhi-Ming Shao
    Citation: Journal of Hematology & Oncology 2021 14:98
    Content type: Review Published on:

  29. T cell acute lymphoblastic leukemia (T-ALL) is a high-risk subtype that comprises 10–15% of childhood and 20–25% of adult ALL cases. Over 70% of T-ALL patients harbor activating mutations in the NOTCH1 signali...

    Authors: Inge Govaerts, Cristina Prieto, Charlien Vandersmissen, Olga Gielen, Kris Jacobs, Sarah Provost, David Nittner, Johan Maertens, Nancy Boeckx, Kim De Keersmaecker, Heidi Segers and Jan Cools
    Citation: Journal of Hematology & Oncology 2021 14:97
    Content type: Research Published on:

  30. Older patients (≥ 60 years) with acute myeloid leukemia (AML) often have multiple, sequentially acquired, somatic mutations that drive leukemogenesis and are associated with poor outcome. Beat AML is a Leukemi...

    Authors: Alice S. Mims, Jessica Kohlschmidt, Uma Borate, James S. Blachly, Shelley Orwick, Ann-Kathrin Eisfeld, Dimitrios Papaioannou, Deedra Nicolet, Krzysztof Mrόzek, Eytan Stein, Bhavana Bhatnagar, Richard M. Stone, Jonathan E. Kolitz, Eunice S. Wang, Bayard L. Powell, Amy Burd…
    Citation: Journal of Hematology & Oncology 2021 14:96
    Content type: Research Published on:

  31. Monoclonal antibodies targeting programmed death ligand 1 (PD-L1) signaling currently approved for defective mismatch repair (dMMR)/microsatellite instability high (MSI-H) tumors must be delivered by intraveno...

    Authors: Jian Li, Yanhong Deng, Weijie Zhang, Ai-Ping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, David Liu and Lin Shen
    Citation: Journal of Hematology & Oncology 2021 14:95
    Content type: Rapid communication Published on:

  32. The natural course of untreated chronic myeloid leukemia (CML) is progression to an aggressive blast phase. Even in the current era of BCR-ABL1 tyrosine kinase inhibitors (TKIs), the outcomes of blast phase CM...

    Authors: Kapil Saxena, Elias Jabbour, Ghayas Issa, Koji Sasaki, Farhad Ravandi, Abhishek Maiti, Naval Daver, Tapan Kadia, Courtney D. DiNardo, Marina Konopleva, Jorge E. Cortes, Musa Yilmaz, Kelly Chien, Sherry Pierce, Hagop Kantarjian and Nicholas J. Short
    Citation: Journal of Hematology & Oncology 2021 14:94
    Content type: Research Published on:

  33. Small non-coding RNAs (ncRNAs) are vital regulators of biological activities, and aberrant levels of small ncRNAs are commonly found in precancerous lesions and cancer. PIWI-interacting RNAs (piRNAs) are a nov...

    Authors: Silu Chen, Shuai Ben, Junyi Xin, Shuwei Li, Rui Zheng, Hao Wang, Lulu Fan, Mulong Du, Zhengdong Zhang and Meilin Wang
    Citation: Journal of Hematology & Oncology 2021 14:93
    Content type: Review Published on:

  34. Hypoxia inducible factor-1α (HIF-1α) up-regulates the expression of programmed death ligand-1 (PD-L1) in some extracranial malignancies. However, whether it could increase PD-L1 expression in intracranial tumo...

    Authors: Xing-chen Ding, Liang-liang Wang, Xue-dong Zhang, Jun-long Xu, Pei-feng Li, Hua Liang, Xian-bin Zhang, Li Xie, Zi-han Zhou, Jia Yang, Ralph R. Weichselbaum, Jin-ming Yu and Man Hu
    Citation: Journal of Hematology & Oncology 2021 14:92
    Content type: Letter to the Editor Published on:

  35. Single-cell sequencing, including genomics, transcriptomics, epigenomics, proteomics and metabolomics sequencing, is a powerful tool to decipher the cellular and molecular landscape at a single-cell resolution...

    Authors: Yalan Lei, Rong Tang, Jin Xu, Wei Wang, Bo Zhang, Jiang Liu, Xianjun Yu and Si Shi
    Citation: Journal of Hematology & Oncology 2021 14:91
    Content type: Review Published on:

  36. The chimera antigen receptor (CAR) T cell therapy is a novel and potential targeted therapy and has achieved satisfactory efficacy in patients with relapsed or refractory multiple myeloma (MM) in recent years....

    Authors: Mengying Ke, Liqing Kang, Ling Wang, Shu Yang, Yajun Wang, Haiyan Liu, Chunyan Gu, Hongming Huang and Ye Yang
    Citation: Journal of Hematology & Oncology 2021 14:90
    Content type: Letter to the Editor Published on:

  37. Accurate appraisal of burden of adolescents and young adults (AYAs) cancers is crucial to informing resource allocation and policy making. We report on the latest estimates of burden of AYA cancers in 204 cou...

    Authors: Yi Feng Wen, Meng Xuan Chen, Guosheng Yin, Ruitao Lin, Yu Jie Zhong, Qian Qian Dong and Hai Ming Wong
    Citation: Journal of Hematology & Oncology 2021 14:89
    Content type: Research Published on:

  39. Cases of thrombotic thrombocytopenia induced by coronavirus disease 2019 (COVID-19) vaccines have been reported recently. Herein, we describe the first case of another critical disorder, hemophagocytic lymphoh...

    Authors: Liang V. Tang and Yu Hu
    Citation: Journal of Hematology & Oncology 2021 14:87
    Content type: Letter to the Editor Published on:

  40. Vaccination for SARS-CoV-2 provides significant protection against the infection in the general population. However, only limited data exist for patients with cancer under systemic therapy. Based on this, our ...

    Authors: Evangelos Terpos, Flora Zagouri, Michalis Liontos, Aimilia D. Sklirou, Konstantinos Koutsoukos, Christos Markellos, Alexandros Briasoulis, Eleni-Dimitra Papanagnou, Ioannis P. Trougakos and Meletios-Athanasios Dimopoulos
    Citation: Journal of Hematology & Oncology 2021 14:86
    Content type: Letter to the Editor Published on:

  42. There is no information on the impact of donor type in allogeneic hematopoietic stem cell transplantation (HCT) using homogeneous graft-versus-host (GVHD) prophylaxis with post-transplant cyclophosphamide (PTC...

    Authors: Jaime Sanz, Jacques-Emmanuel Galimard, Myriam Labopin, Boris Afanasyev, Moiseev Ivan Sergeevich, Emanuele Angelucci, Nicolaus Kröger, Yener Koc, Fabio Ciceri, J. L. Diez-Martin, Mutlu Arat, Simona Sica, Montserrat Rovira, Mahmoud Aljurf, Johanna Tischer, Bipin Savani…
    Citation: Journal of Hematology & Oncology 2021 14:84
    Content type: Research Published on:

  43. Challenges remain on the selection of patients who potentially respond to a class of drugs that target epigenetics for cancer treatment. This study aims to investigate TET2/DNMT3A mutations and antitumor activity...

    Authors: Sherry X. Yang, Melinda Hollingshead, Larry Rubinstein, Dat Nguyen, Angelo B. A. Larenjeira, Robert J. Kinders, Michael Difilippantonio and James H. Doroshow
    Citation: Journal of Hematology & Oncology 2021 14:83
    Content type: Research Published on:

  44. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative treatment for acute myeloid leukemia (AML). However, most patients experience relapse after allo-HSCT, with a poor progn...

    Authors: Qingya Cui, Chongsheng Qian, Nan Xu, Liqing Kang, Haiping Dai, Wei Cui, Baoquan Song, Jia Yin, Zheng Li, Xiaming Zhu, Changju Qu, Tianhui Liu, Wenhong Shen, Mingqing Zhu, Lei Yu, Depei Wu…
    Citation: Journal of Hematology & Oncology 2021 14:82
    Content type: Letter to the Editor Published on:

  45. Safety and immunogenicity of BNT162b2 mRNA vaccine are unknown in hematological patients; both were evaluated prospectively in 42 patients with multiple myeloma (MM) and 50 with myeloproliferative malignancies...

    Authors: Fulvia Pimpinelli, Francesco Marchesi, Giulia Piaggio, Diana Giannarelli, Elena Papa, Paolo Falcucci, Martina Pontone, Simona Di Martino, Valentina Laquintana, Antonia La Malfa, Enea Gino Di Domenico, Ornella Di Bella, Gianluca Falzone, Fabrizio Ensoli, Branka Vujovic, Aldo Morrone…
    Citation: Journal of Hematology & Oncology 2021 14:81
    Content type: Research Published on:

  46. Precise methods for postoperative risk stratification to guide the administration of adjuvant chemotherapy (ACT) in localized colorectal cancer (CRC) are still lacking. Here, we conducted a prospective, observ...

    Authors: Gong Chen, Junjie Peng, Qian Xiao, Hao-Xiang Wu, Xiaojun Wu, Fulong Wang, Liren Li, Peirong Ding, Qi Zhao, Yaqi Li, Da Wang, Yang Shao, Hua Bao, Zhizhong Pan, Ke-Feng Ding, Sanjun Cai…
    Citation: Journal of Hematology & Oncology 2021 14:80
    Content type: Research Published on:

  47. Long known as digestive organelles, lysosomes have now emerged as multifaceted centers responsible for degradation, nutrient sensing, and immunity. Growing evidence also implicates role of lysosome-related mec...

    Authors: Ziqi Zhang, Pengfei Yue, Tianqi Lu, Yang Wang, Yuquan Wei and Xiawei Wei
    Citation: Journal of Hematology & Oncology 2021 14:79
    Content type: Review Published on:

  48. Co-stimulatory and co-inhibitory molecules play a critical role in T cell function. Tumor cells escape immune surveillance by promoting immunosuppression. Immunotherapy targeting inhibitory molecules like anti...

    Authors: Julian A. Marin-Acevedo, ErinMarie O. Kimbrough, Rami Manochakian, Yujie Zhao and Yanyan Lou
    Citation: Journal of Hematology & Oncology 2021 14:78
    Content type: Review Published on:

  50. IDH1 and IDH2 mutations (IDH1/2Mut) are recognized as recurrent genetic alterations in acute myeloid leukemia (AML) and associated with both clinical impact and therapeutic opportunity due to the recent developme...

    Authors: Mathieu Simonin, Aline Schmidt, Christophe Bontoux, Marie-Émilie Dourthe, Etienne Lengliné, Guillaume P. Andrieu, Ludovic Lhermitte, Carlos Graux, Nathalie Grardel, Jean-Michel Cayuela, Françoise Huguet, Isabelle Arnoux, Stéphane Ducassou, Elizabeth Macintyre, Virginie Gandemer, Hervé Dombret…
    Citation: Journal of Hematology & Oncology 2021 14:74
    Content type: Rapid communication Published on:
JHO logo
Submit manuscript

Follow

Annual Journal Metrics

  • 2022 Citation Impact
    28.5 - 2-year Impact Factor
    23.1 - 5-year Impact Factor
    4.045 - SNIP (Source Normalized Impact per Paper)
    6.046 - SJR (SCImago Journal Rank)

    2023 Speed
    5 days submission to first editorial decision for all manuscripts (Median)
    59 days submission to accept (Median)

    2023 Usage 
    3,173,795 downloads
    2,671 Altmetric mentions

On the blog

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here. 

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us